| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10741-012-9323-1 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s10741-012-9323-1 |
| P698 | PubMed publication ID | 22622468 |
| P50 | author | Adriaan A Voors | Q91537232 |
| Lothar Roessig | Q114291624 | ||
| Hani N Sabbah | Q114291627 | ||
| Catherine N Marti | Q114321794 | ||
| Stephen J Greene | Q125217678 | ||
| Piotr Ponikowski | Q22114836 | ||
| Phillip D Levy | Q89918839 | ||
| Gregg C. Fonarow | Q38543909 | ||
| Marco Metra | Q39274051 | ||
| Umberto Campia | Q57317630 | ||
| Mihai Gheorghiade | Q60059386 | ||
| Bertram Pitt | Q63107334 | ||
| Javed Butler | Q63107356 | ||
| Johannes-Peter Stasch | Q66360867 | ||
| P2093 | author name string | Naoki Sato | |
| John G F Cleland | |||
| Michael Böhm | |||
| Sean P Collins | |||
| John C Burnett | |||
| Academic Research Team in Heart Failure (ART-HF) | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association | Q22306345 |
| NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential | Q24656131 | ||
| Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase | Q27661554 | ||
| Coronary endothelial dysfunction in patients with acute-onset idiopathic dilated cardiomyopathy | Q32052640 | ||
| NO-independent regulatory site on soluble guanylate cyclase | Q32165040 | ||
| Stimulation of soluble guanylyl cyclase inhibits mesangial cell proliferation and matrix accumulation in experimental glomerulonephritis | Q33209298 | ||
| Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial | Q34003169 | ||
| Endothelial dysfunction in chronic heart failure: some new basic mechanisms. | Q34075545 | ||
| Soluble guanylate cyclase agonists inhibit expression and procoagulant activity of tissue factor | Q34122462 | ||
| Acute heart failure syndromes: current state and framework for future research | Q34478054 | ||
| Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure | Q34572385 | ||
| NO-independent, haem-dependent soluble guanylate cyclase stimulators | Q34906036 | ||
| Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension | Q34957241 | ||
| Endothelial nitric oxide synthase overexpression attenuates congestive heart failure in mice | Q34961540 | ||
| Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels | Q35009484 | ||
| Deconstructing endothelial dysfunction: soluble guanylyl cyclase oxidation and the NO resistance syndrome | Q35009508 | ||
| Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease | Q35010064 | ||
| Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies | Q35044037 | ||
| Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies | Q35044042 | ||
| Nitric oxide and cardiac function: ten years after, and continuing | Q35213031 | ||
| Nitric oxide's role in the heart: control of beating or breathing? | Q35813373 | ||
| Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment. | Q36018283 | ||
| Nitrosative stress and pharmacological modulation of heart failure | Q36145124 | ||
| Prognostic markers in heart failure--congestion, neurohormones, and the cardiorenal syndrome | Q36950077 | ||
| Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans | Q37088937 | ||
| Endothelial dysfunction and vascular disease | Q37394140 | ||
| Cell death in the pathogenesis of heart disease: mechanisms and significance | Q37690704 | ||
| Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis | Q37692538 | ||
| Cardiorenal syndrome: new perspectives | Q37765094 | ||
| Urinary L-type fatty acid-binding protein as a new renal biomarker in critical care | Q37782231 | ||
| Is oxidative stress a therapeutic target in cardiovascular disease? | Q37803047 | ||
| NO-independent activation of soluble guanylate cyclase prevents disease progression in rats with 5/6 nephrectomy | Q38758203 | ||
| Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. | Q39675412 | ||
| The prognostic importance of endothelial dysfunction and carotid atheroma burden in patients with coronary artery disease | Q40561664 | ||
| Basic mechanisms in heart failure: the cytokine hypothesis | Q41188647 | ||
| Endothelium-dependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. | Q41224359 | ||
| Expression and activity of soluble guanylate cyclase in injury and repair of anti-thy1 glomerulonephritis | Q42471113 | ||
| Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis | Q42479831 | ||
| Hemodynamic stresses induce endothelial dysfunction and remodeling of pulmonary artery in experimental compensated heart failure | Q42489094 | ||
| Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models | Q42976720 | ||
| Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure | Q42987368 | ||
| NO-independent stimulators of soluble guanylate cyclase | Q43558550 | ||
| Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction | Q43746731 | ||
| Influence of nitric oxide synthase and adrenergic inhibition on adenosine-induced myocardial hyperemia | Q43790677 | ||
| Prognostic value of coronary vascular endothelial dysfunction | Q44090667 | ||
| Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure | Q44310085 | ||
| Abnormal coronary microvascular endothelial function in humans with asymptomatic left ventricular dysfunction | Q44567991 | ||
| Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes | Q44657274 | ||
| A high-fat, refined-carbohydrate diet induces endothelial dysfunction and oxidant/antioxidant imbalance and depresses NOS protein expression | Q45034242 | ||
| Additional stimulation of sGC on top of standard treatment with ARB`s may offer a new therapeutic approach for the treatment of diabetic nephropathy resistant to ARB treatment alone. | Q45928509 | ||
| Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. | Q46006828 | ||
| Pressure-independent effects of pharmacological stimulation of soluble guanylate cyclase on fibrosis in pressure-overloaded rat heart. | Q46020956 | ||
| Handbook of Experimental Pharmacology 191. cGMP: generators, effectors and therapeutic implications. Preface | Q46133957 | ||
| Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition | Q46622392 | ||
| Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice | Q46702844 | ||
| Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure | Q46793768 | ||
| Biochemistry and pharmacology of novel anthranilic acid derivatives activating heme-oxidized soluble guanylyl cyclase | Q46839590 | ||
| NO-insensitive sGCbeta1 H105F knockin mice: if NO has no place to go. | Q46857350 | ||
| Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure | Q47863806 | ||
| Flow-mediated vasodilation predicts outcome in patients with chronic heart failure: comparison with B-type natriuretic peptide. | Q48767724 | ||
| Myocardial contractile response to nitric oxide and cGMP. | Q50751033 | ||
| Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. | Q54088553 | ||
| Regular physical exercise corrects endothelial dysfunction and improves exercise capacity in patients with chronic heart failure. | Q54112883 | ||
| Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. | Q54173625 | ||
| Cardioprotective effects in aged spontaneously hypertensive rats due to chronic stimulation/activation of sGC without hypotension. | Q55211329 | ||
| Phase III clinical trial end points in acute heart failure syndromes: A virtual roundtable with the acute heart failure syndromes international working group | Q57396271 | ||
| Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC | Q57716667 | ||
| Endothelial nitric oxide synthase limits left ventricular remodeling after myocardial infarction in mice. | Q64980431 | ||
| Diminished endothelium-derived relaxing factor activity in an experimental model of chronic heart failure | Q68033329 | ||
| Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes | Q71006353 | ||
| Endothelial Control of Arterial Distensibility Is Impaired in Chronic Heart Failure | Q71807619 | ||
| 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes | Q72360226 | ||
| Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion | Q72677207 | ||
| Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management | Q73030712 | ||
| Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha | Q73168743 | ||
| Apoptosis in the failing human heart | Q73215232 | ||
| Effects of the nitric oxide donor sodium nitroprusside on intracellular pH and contraction in hypertrophied myocytes | Q73321042 | ||
| Endothelial dysfunction in patients with heart failure: relationship to disease severity | Q73622513 | ||
| Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease | Q73708513 | ||
| Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure : role of nitric oxide, prostanoids, oxidant stress, and bradykinin | Q74014449 | ||
| Limb blood flow during exercise is dependent on nitric oxide | Q77123091 | ||
| Pulsatile hemodynamics in congestive heart failure | Q77373392 | ||
| Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index | Q79125172 | ||
| Targeting heme-oxidized soluble guanylate cyclase: solution for all cardiorenal problems in heart failure? | Q79837496 | ||
| Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats | Q80284464 | ||
| Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage | Q80492373 | ||
| Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death | Q81190763 | ||
| Chronic heart failure is associated with vascular remodeling of the brachial artery | Q81251857 | ||
| P433 | issue | 2 | |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 123-134 | |
| P577 | publication date | 2013-03-01 | |
| P1433 | published in | Heart Failure Reviews | Q2167497 |
| P1476 | title | Soluble guanylate cyclase: a potential therapeutic target for heart failure | |
| P478 | volume | 18 |
| Q49718583 | A diseasome cluster-based drug repurposing of soluble guanylate cyclase activators from smooth muscle relaxation to direct neuroprotection. |
| Q89179169 | Asymmetric dimethylarginine (ADMA) as an important risk factor for the increased cardiovascular diseases and heart failure in chronic kidney disease |
| Q91837469 | Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial |
| Q26853363 | Cardiac endothelium-myocyte interaction: clinical opportunities for new heart failure therapies regardless of ejection fraction |
| Q38737757 | Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure |
| Q35138860 | Cyclic nucleotide signalling in kidney fibrosis |
| Q52670776 | Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding. |
| Q37245523 | Effect of asymmetric dimethylarginine (ADMA) on heart failure development |
| Q27021649 | Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS |
| Q38612665 | From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015. |
| Q39080324 | GRK2 as negative modulator of NO bioavailability: Implications for cardiovascular disease |
| Q27677544 | Insights into BAY 60-2770 Activation and S -Nitrosylation-Dependent Desensitization of Soluble Guanylyl Cyclase via Crystal Structures of Homologous Nostoc H-NOX Domain Complexes |
| Q36868978 | Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research |
| Q94592130 | Multiparametric Mechanistic Profiling of Inotropic Drugs in Adult Human Primary Cardiomyocytes |
| Q52687612 | Multiple Avenues of Modulating the Nitric Oxide Pathway in Heart Failure Clinical Trials. |
| Q38594785 | New medical therapies for heart failure |
| Q38759494 | New pharmacological approaches in heart failure therapy: developments and possibilities. |
| Q39024203 | Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure |
| Q91988023 | Phase 3 DREAM-HF Trial of Mesenchymal Precursor Cells in Chronic Heart Failure |
| Q30251531 | Potential new drug treatments for congestive heart failure |
| Q38670275 | Protein kinase G signaling in cardiac pathophysiology: Impact of proteomics on clinical trials |
| Q48640874 | Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). |
| Q38161841 | Riociguat: first global approval |
| Q33578212 | Silent disease progression in clinically stable heart failure |
| Q38546917 | Small molecule and peptide therapies for chronic heart failure: a patent review (2011 - 2014). |
| Q38818606 | Soluble Guanylate Cyclase Stimulators: a Novel Treatment Option for Heart Failure Associated with Cardiorenal Syndromes? |
| Q37375441 | The NO/ONOO-cycle as the central cause of heart failure |
| Q38558614 | The Three-Decade Long Journey in Heart Failure Drug Development |
| Q27024279 | The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction |
| Q38214097 | Vasodilators in Acute Heart Failure: Review of the Latest Studies |
Search more.